Picropodophyllotoxin or Podophyllotoxin Does Not Induce Cell Death via Insulin-like Growth Factor-I Receptor
To the Editor:
The cyclolignan picropodophyllotoxin (PPP) was recently launched as an anticancer drug specifically targeting insulin-like growth factor-I receptor (IGF-IR; ref. 1). PPP is an epimer of podophyllotoxin (PPT), an established inhibitor of microtubule assembly used to treat genital warts. PPT binds to the colchicine binding site of tubulin (2) . PPT-resistant cells are cross-resistant to colchicine, colcemid, and vinblastine (3). PPP is 20-to 50-fold less potent than PPT in inhibition of microtubule assembly (4) and the GI 50 of PPP is %50-fold that of PPT (%500 versus %10 nmol/L). This would be expected if growth inhibition by PPP is due to microtubule inhibition (discussed in ref.
3). Also consistent with this notion is that PPT-resistant cells are resistant to PPP (3) .
Despite the documented microtubule effects, an association between IGF-IR expression and sensitivity to PPT/PPP was reported (1). Eleven cell types expressing IGF-IR were found sensitive to PPP, and three cell types lacking IGF-IR expression were resistant in vitro and/or in vivo (1). The in vitro GI 50 for cell types lacking IGF-IR expression (RÀ cells, HepG2 cells) was >15 Amol/L for both drugs (1).
S. Linder and M. C. Shoshan reexamined PPT/PPP effects on IGF-IR-deficient RÀ cells, which were reported resistant to 15 Amol/L PPT/PPP (1). RÀ cells ( from Dr. Renato Baserga, Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA) and mouse embryo fibroblasts (MEFs) were exposed to 0.5 Amol/L PPT or PPP ( from Dr. Girnita, Department of Oncology-Pathology, Karolinska Institute, Stockholm, Sweden), a concentration used to inhibit IGF-IR (5). Both cell types were equally sensitive; PPP reduced viability of R1À cells to 52.6 F 7.5% of control and of MEFs to 58.3 F 6.4% of control, whereas PPT reduced viability to 51.8 F 2.2% and 58.3 F 6.4% of control, respectively [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay; 40 h]. Four independent experiments yielded similar results. Both drugs induced sub-G 1 debris in RÀ cells, indicative of cell death (PPT, 64% of total counts; PPP, 56%; controls, 6%). PPT treatment of cancer is limited by severe side effects. Although IGF-IR is an attractive cancer therapy target, our data showing that PPTand PPP induce loss of viability and cell death in IGF-IR-deficient cells contest their potential as IGF-IR-specific anticancer drugs.
